PREVIEW-Astra, Boehringer may steal show at heart congress
* AstraZeneca's Brilinta vies for Plavix market share
* Boehringer's Pradaxa aims to replace warfarin
* New drugs competitors for Eli Lilly, Bayer
* Clinical data due Aug. 30 in Barcelona
By Ben Hirschler, European Pharmaceuticals Correspondent
LONDON, Aug 24 (Reuters) - The sickly pharmaceuticals sector could get a shot in the arm next weekend if two new heart drugs from Anglo-Swedish AstraZeneca (AZN.L: Quote, Profile, Research) and unlisted German group Boehringer Ingelheim live up to expectations.
AstraZeneca aims to show at a big cardiology congress in Barcelona that its experimental blood thinner Brilinta has a clear edge over Sanofi-Aventis (SASY.PA: Quote, Profile, Research) and Bristol-Myers Squibb's (BMY.N: Quote, Profile, Research) Plavix, while Boehringer will showcase Pradaxa.
In both cases, billions of dollars are at stake. Continued...
India Investment Summit 2009
Top executives and bankers discuss their own plans and the broader opportunities and challenges for India during the Reuters India Investment Summit in Mumbai and Bangalore. Full Coverage | Blog
PLAYBOY SALE
An icon bows to changing times
With his Playboy Enterprises in talks to be sold for about $300 million, the 83 year-old Hugh Hefner will be giving up control over the iconic adult entertainment empire he founded that was instrumental in shaping society's opinions on nudity, sex and free speech. Full Article
India
US
UK
